Skip to content

Designed to deliver Qlosi-clear moments in every drop

Provide your presbyopia patients with clear near vision on their terms*

*Patients can use one drop of Qlosi in each eye. This can be repeated a second time after 2 to 3 hours for an effect up to 8 hours

Qlosi is designed for the patients you see every day—adults who are affected by presbyopia and want relief from their readers.

With Qlosi, patients can experience improved near vision, without compromising distance vision1

Ready to prescribe Qlosi?
 
Find out how much your patients can save on Qlosi and see offers available for you
Qlosi may help patients like these find relief from their readers.

Important Safety Information

Expand

Indication and Usage

 

Qlosi™ (pilocarpine hydrochloride ophthalmic solution) 0.4%, for topical ophthalmic use is a cholinergic receptor agonist indicated for the treatment of presbyopia in adults.

 

Important Safety Information

Contraindications

Hypersensitivity

 

Warnings and Precautions

Advise patients to not drive or operate machinery if vision is not clear (e.g., blurred vision). Exercise caution in night driving and other hazardous occupations in poor illumination.

 

Rare cases of retinal detachment have been reported with miotics. Examination of the retina is advised in all patients prior to initiation of therapy. Advise patients to seek immediate medical care with sudden onset of flashes of lights, floaters, or vision loss.

 

Qlosi is not recommended to be used when iritis is present.

 

Qlosi should not be administered while wearing contact lenses. Remove lenses prior to the installation of Qlosi and wait 10 minutes before reinsertion.

 

Avoid touching the tip of the vial to the eye or any other surface.

 

Adverse Reactions

The most common adverse reactions (5% to 8%) are instillation site pain and headaches.

 

Please see full Prescribing Information here: qlosi.com/prescribing-information

References

  1. Holland E, Karpecki P, Fingeret M, et al. Efficacy and Safety of CSF-1 (0.4% Pilocarpine Hydrochloride) in Presbyopia: Pooled Results of the NEAR Phase 3 Randomized, Clinical Trials. Clin Ther. 2024;46(2):104-113. doi:10.1016/j.clinthera.2023.12.005
  2. Qlosi [package insert]. Ponte Verda, FL. Orasis Pharmaceuticals.